Preferred Label : Belrestotug;
NCIt synonyms : Anti-TIGIT Monoclonal Antibody EOS884448;
NCIt definition : A human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule
and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and
immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential
immune checkpoint inhibitory and anti-tumor activities. Upon administration, belrestotug
targets and binds to TIGIT expressed on various immune cells, including tumor-infiltrating
lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112
(nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor;
PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155
with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is
expressed on immune cells, such as natural killer (NK) cells and CD8 T-cells. This
leads to CD226 dimerization and CD226-mediated signaling and activates the immune
system to exert a T-cell-mediated immune response against cancer cells. In addition,
belrestotug may preferentially deplete immunosuppressive, TIGIT-expressing regulatory
T-cells (Tregs) through Fc gamma receptor interaction and antibody-dependent cellular
cytotoxicity (ADCC). This may further enhance anti-tumor activity. TIGIT, a member
of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role
in the suppression of T-cell proliferation and activation; it is involved in tumor
cell immune evasion, and the inhibition of antiviral immune responses.;
UNII : 59HAW3EQ4C;
CAS number : 2574438-65-4;
Molecule name : EOS-448; EOS-884448; EOS 884448; WB 2127; GSK-4428859A; WB-2127; GSK 4428859A;
NCI Metathesaurus CUI : CL1642581;
Origin ID : C176746;
UMLS CUI : C5706693;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
